Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-FLOT (panitumumab + docetaxel + 5-FU + leucovorin + oxaliplatin) in KRAS wild-type metastatic or locally advanced gastric or gastroesophageal junction adenocarcinoma
2010-018993-20Phase 2Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and gastric cancer (GC), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: objective remission rate. Started May 2012; status: completed.
02
Drugs
panitumumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2010-018993-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018993-20.